How PD-1 antibody therapy affects immune function in cancer
Part of Cancer, Immune system & allergy clinical trials.
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of cancer (malignant tumor).
- Your medical records are complete and available.
- You have immune function test results that can be checked.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
This early-phase study tests an anti–PD-1 antibody, either alone or with decitabine or chemotherapy, in people whose cancer has come back or isn’t responding to treatment. It may help your immune system attack the cancer, especially after prior therapies.
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
This study looks at how well immunotherapy (a type of cancer treatment that helps your immune system attack cancer cells) works for people with various types of cancer. You may join if you are already planning to receive this treatment, and the study will track your outcomes to help improve future care.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.